Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGA: Stereotactic Accelerated Radiotherapy in Glioblastoma
NCT05781321Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Overall Survival at 12 months. Started Mar 2023; status: active, not recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05781321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781321.